CD19 and neoplasm: Despite the application of CD19-directed CAR-T cells having shown remarkable success in the treatment of CD19+ B cell malignancies, there are some obstacles to this method for solid tumors due to the heterogeneity of antigens expressed in solid tumors (Chan et al., 2021) and the immunosuppressive tumor microenvironment (Yeku et al., 2017).